Colorado-based Kazmira Therapeutics introduces a new standard in virtual medical cannabis education for patients & prescribing medical providers
DENVER, April 21, 2026 /PRNewswire/ — Today Kazmira Therapeutics announced the official launch of 1Cannabis, an online medical cannabis education platform. This e-learning platform features two clinician-focused programs designed to help providers navigate the novel prescription cannabinoid (CBD) landscape, along with a patient-focused program centered on medicinal CBD, with a particular emphasis on cannabidiol.
The 1Cannabis programs offer clinicians the opportunity to engage in evidence-based clinical conversations grounded in physiology, safety, and best practices, while equipping patients with the education needed to understand why medical cannabis care is categorically different from retail CBD. Clinical access will expand through Cope Now, with telemedicine services launching in May.
Kazmira co-founder and co-CEO Pulak Sharma said the evidence-based programs will help ensure clinicians are receiving the most up-to-date information about medicinal CBD. “Patient demand for cannabinoid therapies is well established and accelerating. What has been missing is the clinical infrastructure – licensed providers, compounding pharmacies, and therapeutic dosing – that patients deserve. The education gap for clinicians has been a critical barrier,” Sharma said. “From my conversation with primary care physicians, they face substantial regulatory and administrative barriers when prescribing controlled substances like opioids and benzodiazepines today – and those barriers are only growing. Their patients are asking for alternatives with better safety profiles and less dependency. Compounded CBD, prescribed through a supervised clinical pathway, is one of the most promising options available to these physicians. The problem has always been that physicians had nowhere to go to get credible, evidence-based training. 1Cannabis closes that gap.”
1Cannabis consists of three programs:
-
The CBD001: cannabinoid basics explained 30-minute program for patients offers a clear, foundational understanding of CBD.
-
The CBD101: core cannabinoid fundamentals 90-minute program for providers covers the endocannabinoid system, safety, and drug interactions.
-
The CBD201: clinical protocols & patient populations program for providers offers real-world clinical considerations and specific patient population protocols that bridge the gap between theory and practice.
“When physicians have the right information, it opens the door for judgment-free, informed conversations with patients,” said Dr. Rachit Marwaha, Board Certified MD and a medical advisor to Kazmira Therapeutics. He went on to explain that a recent report published in JAMA found that only 5 percent of patients using cannabis for health reasons had it documented in their electronic medical record. “It is crucial for providers to know what medicines and over-the-counter products a patient is taking to ensure that proposed treatment plans and medications won’t interact negatively,” Marwaha added.
